ADMA Biologics Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADMA Biologics stock.
View analyst ratings for ADMA Biologics or view top-rated stocks.

Wall Street analysts have given ADMA Biologics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ADMA Biologics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ADMA Biologics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for ADMA Biologics.

ADMA Biologics, Inc. (NASDAQ:ADMA) posted its quarterly earnings results on Tuesday, May, 11th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.01. The biotechnology company had revenue of $16.05 million for the quarter, compared to the consensus estimate of $15.63 million. ADMA Biologics had a negative trailing twelve-month return on equity of 85.82% and a negative net margin of 155.78%.
View ADMA Biologics' earnings history.

ADMA Biologics' stock was trading at $2.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ADMA stock has decreased by 21.2% and is now trading at $1.82.
View which stocks have been most impacted by COVID-19.

ADMA Biologics issued an update on its FY 2024 After-Hours earnings guidance on Thursday, March, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $250 million.

5 analysts have issued 1 year price objectives for ADMA Biologics' shares. Their forecasts range from $6.00 to $11.00. On average, they anticipate ADMA Biologics' stock price to reach $7.80 in the next year. This suggests a possible upside of 328.6% from the stock's current price.
View analysts' price targets for ADMA Biologics or view top-rated stocks among Wall Street analysts.

9 employees have rated ADMA Biologics CEO Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among ADMA Biologics' employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to ADMA Biologics include Taysha Gene Therapies (TSHA), Inhibrx (INBX), CEL-SCI (CVM), Sutro Biopharma (STRO), Passage Bio (PASG), Athira Pharma (ATHA), Curis (CRIS), Aerie Pharmaceuticals (AERI), Tarsus Pharmaceuticals (TARS), iTeos Therapeutics (ITOS), Adaptimmune Therapeutics (ADAP), Cellectis (CLLS), DBV Technologies (DBVT), TCR2 Therapeutics (TCRR) and Precision BioSciences (DTIL).
View all of ADMA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), Cannabics Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

ADMA Biologics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Nuveen Asset Management LLC (5.57%), BlackRock Inc. (4.74%), Geode Capital Management LLC (1.12%), Northern Trust Corp (0.65%), Schonfeld Strategic Advisors LLC (0.57%) and Squarepoint Ops LLC (0.47%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen and Perceptive Advisors Llc.
View institutional ownership trends for ADMA Biologics.

ADMA stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Prosight Management LP, Alyeska Investment Group L.P., Thrivent Financial for Lutherans, Northern Trust Corp, Los Angeles Capital Management LLC, New York Life Investments Alternatives, and AE Wealth Management LLC.
View insider buying and selling activity for ADMA Biologics or view top insider-selling stocks.

ADMA stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Squarepoint Ops LLC, Geode Capital Management LLC, Clearline Capital LP, BlackRock Inc., GSA Capital Partners LLP, Morgan Stanley, and Barclays PLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, and Perceptive Advisors Llc.
View insider buying and selling activity for ADMA Biologics or or view top insider-buying stocks.

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADMA stock can currently be purchased for approximately $1.82.

ADMA Biologics has a market capitalization of $233.31 million and generates $42.22 million in revenue each year. The biotechnology company earns $-75,750,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

ADMA Biologics employs 406 workers across the globe.

The official website for ADMA Biologics is www.admabiologics.com.

ADMA Biologics is headquartered at 465 STATE ROUTE 17, RAMSEY NJ, 07446.

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]